TM9SF1
gene geneOn this page
Also known as MP70HMP70
Summary
TM9SF1 (transmembrane 9 superfamily member 1, HGNC:11864) is a protein-coding gene on chromosome 14q12, encoding Transmembrane 9 superfamily member 1 (O15321). Plays an essential role in autophagy.
Predicted to be involved in protein localization to membrane. Predicted to be located in autophagosome membrane; cytoplasmic vesicle; and lysosomal membrane. Predicted to be active in membrane.
Source: NCBI Gene 10548 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 93 total
- MANE Select transcript:
NM_006405
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:11864 |
| Approved symbol | TM9SF1 |
| Name | transmembrane 9 superfamily member 1 |
| Location | 14q12 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MP70, HMP70 |
| Ensembl gene | ENSG00000100926 |
| Ensembl biotype | protein_coding |
| OMIM | 618965 |
| Entrez | 10548 |
Gene structure
Transcript identifiers
Ensembl transcripts: 26 — 24 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron
ENST00000261789, ENST00000396854, ENST00000524835, ENST00000525592, ENST00000528010, ENST00000528669, ENST00000528895, ENST00000529332, ENST00000530468, ENST00000530563, ENST00000531406, ENST00000532632, ENST00000903983, ENST00000903984, ENST00000903985, ENST00000903986, ENST00000903987, ENST00000903988, ENST00000903989, ENST00000933740, ENST00000933741, ENST00000933742, ENST00000933743, ENST00000933744, ENST00000967639, ENST00000967640
RefSeq mRNA: 3 — MANE Select: NM_006405
NM_001014842, NM_001289006, NM_006405
CCDS: CCDS41934, CCDS73623, CCDS9617
Canonical transcript exons
ENST00000261789 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001419735 | 24195346 | 24195441 |
| ENSE00002152967 | 24189149 | 24189808 |
| ENSE00003467995 | 24192648 | 24193269 |
| ENSE00003479928 | 24192171 | 24192356 |
| ENSE00003563865 | 24190380 | 24190653 |
| ENSE00003628784 | 24194675 | 24195036 |
Expression profiles
Bgee: expression breadth ubiquitous, 180 present calls, max score 95.93.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.7704 / max 132.5334, expressed in 1816 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 142546 | 18.9874 | 1807 |
| 142547 | 12.4982 | 1796 |
| 142545 | 0.2848 | 121 |
Top tissues by expression
246 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| stromal cell of endometrium | CL:0002255 | 95.93 | gold quality |
| islet of Langerhans | UBERON:0000006 | 95.89 | gold quality |
| body of pancreas | UBERON:0001150 | 95.02 | gold quality |
| gall bladder | UBERON:0002110 | 94.20 | gold quality |
| right uterine tube | UBERON:0001302 | 94.08 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 94.06 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 93.97 | gold quality |
| right adrenal gland | UBERON:0001233 | 93.90 | gold quality |
| left adrenal gland | UBERON:0001234 | 93.68 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 93.62 | gold quality |
| pancreas | UBERON:0001264 | 93.55 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 93.23 | gold quality |
| minor salivary gland | UBERON:0001830 | 93.06 | gold quality |
| endocervix | UBERON:0000458 | 92.85 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 92.74 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 92.62 | gold quality |
| body of stomach | UBERON:0001161 | 92.53 | gold quality |
| left uterine tube | UBERON:0001303 | 92.32 | gold quality |
| rectum | UBERON:0001052 | 92.18 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 91.88 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 91.69 | gold quality |
| right coronary artery | UBERON:0001625 | 91.67 | gold quality |
| metanephros cortex | UBERON:0010533 | 91.66 | gold quality |
| body of uterus | UBERON:0009853 | 91.64 | gold quality |
| right lung | UBERON:0002167 | 91.60 | gold quality |
| right ovary | UBERON:0002118 | 91.56 | gold quality |
| ectocervix | UBERON:0012249 | 91.39 | gold quality |
| adrenal gland | UBERON:0002369 | 91.27 | gold quality |
| thoracic aorta | UBERON:0001515 | 91.19 | gold quality |
| left coronary artery | UBERON:0001626 | 91.13 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 11.62 |
| E-MTAB-6142 | no | 254.55 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
45 targeting TM9SF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-3671 | 99.90 | 73.04 | 3897 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-891B | 99.59 | 69.81 | 1083 |
| HSA-MIR-3120-3P | 99.54 | 70.28 | 2669 |
| HSA-MIR-365A-3P | 99.43 | 70.02 | 836 |
| HSA-MIR-365B-3P | 99.43 | 70.02 | 836 |
| HSA-MIR-513A-3P | 99.39 | 70.63 | 3620 |
| HSA-MIR-513C-3P | 99.39 | 70.63 | 3620 |
| HSA-MIR-377-3P | 99.37 | 70.18 | 1905 |
| HSA-MIR-6731-5P | 99.28 | 67.42 | 2375 |
| HSA-MIR-8085 | 99.28 | 67.56 | 2362 |
| HSA-MIR-3606-3P | 99.11 | 69.84 | 3254 |
| HSA-MIR-3168 | 99.08 | 67.75 | 1384 |
| HSA-MIR-5000-3P | 98.79 | 65.63 | 1251 |
| HSA-MIR-500A-5P | 98.76 | 69.13 | 1241 |
| HSA-MIR-330-5P | 98.73 | 67.63 | 1788 |
| HSA-MIR-4501 | 98.72 | 67.19 | 921 |
| HSA-MIR-5197-3P | 98.71 | 67.05 | 1905 |
| HSA-MIR-4700-5P | 98.63 | 67.43 | 1915 |
| HSA-MIR-8060 | 98.61 | 66.93 | 1187 |
| HSA-MIR-3689A-5P | 98.35 | 70.12 | 1049 |
| HSA-MIR-3689B-5P | 98.35 | 70.12 | 1049 |
Literature-anchored findings (GeneRIF, showing 1)
- The results of transmission electron microscopy and immunoblotting to examine LC3-II levels further confirmed the ability of TM9SF1 to induce autophagy. (PMID:19029833)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tm9sf1 | ENSDARG00000022970 |
| mus_musculus | Tm9sf1 | ENSMUSG00000002320 |
| rattus_norvegicus | Tm9sf1 | ENSRNOG00000019710 |
Paralogs (3): TM9SF3 (ENSG00000077147), TM9SF4 (ENSG00000101337), TM9SF2 (ENSG00000125304)
Protein
Protein identifiers
Transmembrane 9 superfamily member 1 — O15321 (reviewed: O15321)
Alternative names: MP70 protein family member
All UniProt accessions (10): O15321, E9PJC4, E9PJM1, E9PL78, E9PMQ9, E9PNW2, E9PP24, E9PQY7, E9PS99, G3V1B9
UniProt curated annotations — full annotation on UniProt →
Function. Plays an essential role in autophagy.
Subcellular location. Lysosome membrane. Cytoplasmic vesicle. Autophagosome membrane.
Tissue specificity. Expressed in lung, pancreas, kidney, liver, placenta, skeletal muscle, heart and brain. The amount in skeletal muscle, heart and brain were considerably lower than in the other tissues.
Similarity. Belongs to the nonaspanin (TM9SF) (TC 8.A.68) family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| O15321-1 | 1 | yes |
| O15321-2 | 2 |
RefSeq proteins (3): NP_001014842, NP_001275935, NP_006396* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR004240 | EMP70 | Family |
Pfam: PF02990
UniProt features (20 total): transmembrane region 9, glycosylation site 3, sequence conflict 3, sequence variant 2, signal peptide 1, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-O15321-F1 | 84.47 | 0.54 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (3): 178, 401, 559
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 148 (showing top):
MORF_RAB5A, KAAB_FAILED_HEART_ATRIUM_DN, GOCC_VACUOLAR_MEMBRANE, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, CHANDRAN_METASTASIS_DN, EFC_Q6, chr14q12, TGTGTGA_MIR377, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, MORF_PPP6C, MORF_PPP2R4, RFX1_02, GOBP_LOCALIZATION_WITHIN_MEMBRANE, GRADE_COLON_AND_RECTAL_CANCER_DN, MILI_PSEUDOPODIA_CHEMOTAXIS_DN
GO Biological Process (2): autophagy (GO:0006914), protein localization to membrane (GO:0072657)
GO Molecular Function (0):
GO Cellular Component (5): autophagosome membrane (GO:0000421), lysosomal membrane (GO:0005765), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), lysosome (GO:0005764)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| catabolic process | 1 |
| transmembrane transport | 1 |
| process utilizing autophagic mechanism | 1 |
| intracellular protein localization | 1 |
| localization within membrane | 1 |
| vacuolar membrane | 1 |
| autophagosome | 1 |
| lysosome | 1 |
| lytic vacuole membrane | 1 |
| cellular anatomical structure | 1 |
| cytoplasm | 1 |
| intracellular vesicle | 1 |
| lytic vacuole | 1 |
Protein interactions and networks
STRING
698 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TM9SF1 | EBAG9 | O00559 | 615 |
| TM9SF1 | NSA2 | O95478 | 529 |
| TM9SF1 | TMEM74 | Q96NL1 | 482 |
| TM9SF1 | TMEM174 | Q8WUU8 | 479 |
| TM9SF1 | EVA1A | Q9H8M9 | 479 |
| TM9SF1 | SNAPC2 | Q13487 | 452 |
| TM9SF1 | SZRD1 | Q7Z422 | 434 |
| TM9SF1 | TMEM165 | Q9HC07 | 394 |
| TM9SF1 | CERT1 | Q9Y5P4 | 382 |
| TM9SF1 | HGS | O14964 | 380 |
| TM9SF1 | WDR45B | Q5MNZ6 | 356 |
| TM9SF1 | CHMP2A | O43633 | 350 |
| TM9SF1 | SNF8 | Q96H20 | 350 |
| TM9SF1 | SNX15 | Q9NRS6 | 349 |
| TM9SF1 | RUBCN | Q92622 | 338 |
IntAct
68 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TM9SF1 | MTNR1A | psi-mi:“MI:0915”(physical association) | 0.370 |
| P2RX7 | TM9SF1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| TCOF1 | TM9SF1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| TM9SF1 | RNASEH1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| psi-mi:“MI:0914”(association) | 0.350 | ||
| ESYT2 | psi-mi:“MI:0914”(association) | 0.350 | |
| E5 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| HAX1 | psi-mi:“MI:0914”(association) | 0.350 | |
| MME | psi-mi:“MI:0914”(association) | 0.350 | |
| CLEC2D | TMEM120B | psi-mi:“MI:0914”(association) | 0.350 |
| TMEM223 | psi-mi:“MI:0914”(association) | 0.350 | |
| M | TM9SF1 | psi-mi:“MI:0914”(association) | 0.350 |
| POMK | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| ATP6V1A | psi-mi:“MI:0914”(association) | 0.350 | |
| PLEKHG3 | psi-mi:“MI:0914”(association) | 0.350 | |
| HLA-C | psi-mi:“MI:0914”(association) | 0.350 | |
| C5AR1 | TCAF2 | psi-mi:“MI:0914”(association) | 0.350 |
| OPRL1 | METTL15 | psi-mi:“MI:0914”(association) | 0.350 |
| ATP1B1 | TM9SF1 | psi-mi:“MI:0914”(association) | 0.350 |
| C5AR1 | SLC12A8 | psi-mi:“MI:0914”(association) | 0.350 |
| GPR182 | SLC12A8 | psi-mi:“MI:0914”(association) | 0.350 |
| CLEC2D | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| RTN3 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| TSPAN15 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| DUOXA2 | TMEM131L | psi-mi:“MI:0914”(association) | 0.350 |
| UPK2 | TMEM131L | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (91): TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Two-hybrid), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Affinity Capture-MS), TM9SF1 (Proximity Label-MS), TM9SF1 (Proximity Label-MS), TM9SF1 (Proximity Label-MS), TM9SF1 (Proximity Label-MS), TM9SF1 (Proximity Label-MS)
ESM2 similar proteins: A0A060LAL9, A0A097ZPE6, A0A1I9R3Y5, A2VEI2, A2XVG1, A2YGP6, A4IFE9, A8B479, A8WQT4, B3H7A9, F4I1L3, G1JSL4, O15321, O22585, O22788, O45228, O64407, O65015, O81270, P10538, P31252, P58021, P80363, Q28C60, Q43727, Q5R8F1, Q5R8Y6, Q5Z8Y4, Q623S8, Q66HF2, Q66HG5, Q6DCK1, Q7FAX1, Q7JW12, Q8CD10, Q8IYU8, Q95PZ2, Q99805, Q99P63, Q9CAB7
Diamond homologs: A4IFE9, A5D7E2, F4HW17, F4KIB2, O15321, P58021, Q4KLL4, Q54ZW0, Q5R8F1, Q5R8Y6, Q5RDY2, Q66HF2, Q66HG5, Q8BH24, Q8RWW1, Q92544, Q940G0, Q940S0, Q99805, Q9C5N2, Q9C720, Q9DBU0, Q9ET30, Q9FHT4, Q9HD45, Q9LIC2, Q9Y819, Q9ZPS7, F4JRE0, P32802, Q04562, Q55FP0, Q9FYQ8, Q7YTA6
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Amino acid transport across the plasma membrane | 5 | 26.8× | 1e-04 |
| R-HSA-425366 | 5 | 16.2× | 5e-04 |
| SLC-mediated transmembrane transport | 11 | 11.6× | 4e-07 |
| R-HSA-425393 | 5 | 11.6× | 2e-03 |
| Class A/1 (Rhodopsin-like receptors) | 7 | 9.3× | 5e-04 |
| GPCR ligand binding | 6 | 6.9× | 5e-03 |
| Transport of small molecules | 12 | 5.4× | 1e-04 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| amino acid transport | 8 | 33.3× | 6e-08 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 5 | 14.6× | 4e-03 |
| transport across blood-brain barrier | 5 | 11.9× | 5e-03 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 6 | 10.5× | 4e-03 |
| response to xenobiotic stimulus | 7 | 6.5× | 7e-03 |
| G protein-coupled receptor signaling pathway | 10 | 4.8× | 4e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
93 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 82 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1245 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 14:24189804:TGGCA:T | acceptor_gain | 1.0000 |
| 14:24189805:GGCA:G | acceptor_gain | 1.0000 |
| 14:24189806:GCA:G | acceptor_gain | 1.0000 |
| 14:24189807:CA:C | acceptor_gain | 1.0000 |
| 14:24189807:CAC:C | acceptor_gain | 1.0000 |
| 14:24189808:AC:A | acceptor_loss | 1.0000 |
| 14:24189809:C:CC | acceptor_gain | 1.0000 |
| 14:24189809:CTGTG:C | acceptor_loss | 1.0000 |
| 14:24189811:G:C | acceptor_gain | 1.0000 |
| 14:24190377:TACCT:T | donor_loss | 1.0000 |
| 14:24190378:ACCTG:A | donor_loss | 1.0000 |
| 14:24190556:C:CT | acceptor_gain | 1.0000 |
| 14:24192166:CTCAC:C | donor_loss | 1.0000 |
| 14:24192167:TCA:T | donor_loss | 1.0000 |
| 14:24192168:CA:C | donor_loss | 1.0000 |
| 14:24192169:A:AC | donor_gain | 1.0000 |
| 14:24192169:A:C | donor_loss | 1.0000 |
| 14:24192170:C:CC | donor_gain | 1.0000 |
| 14:24192170:C:CT | donor_loss | 1.0000 |
| 14:24194689:G:C | donor_gain | 1.0000 |
| 14:24189811:G:GC | acceptor_gain | 0.9900 |
| 14:24190654:C:CC | acceptor_gain | 0.9900 |
| 14:24192217:G:A | donor_gain | 0.9900 |
| 14:24192277:A:C | acceptor_gain | 0.9900 |
| 14:24192357:C:CC | acceptor_gain | 0.9900 |
| 14:24192938:C:CT | donor_gain | 0.9900 |
| 14:24192939:C:CT | donor_gain | 0.9900 |
| 14:24193266:CCAC:C | acceptor_gain | 0.9900 |
| 14:24193267:CAC:C | acceptor_gain | 0.9900 |
| 14:24193267:CACC:C | acceptor_gain | 0.9900 |
AlphaMissense
3948 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 14:24189665:A:G | L524S | 1.000 |
| 14:24190396:C:G | G471R | 1.000 |
| 14:24192681:C:G | G312R | 1.000 |
| 14:24192723:A:T | F298I | 1.000 |
| 14:24192745:C:A | W290C | 1.000 |
| 14:24192745:C:G | W290C | 1.000 |
| 14:24192747:A:G | W290R | 1.000 |
| 14:24192747:A:T | W290R | 1.000 |
| 14:24192881:A:T | L245H | 1.000 |
| 14:24192892:G:C | N241K | 1.000 |
| 14:24192892:G:T | N241K | 1.000 |
| 14:24193188:C:G | G143R | 1.000 |
| 14:24194766:C:A | G85V | 1.000 |
| 14:24194766:C:T | G85E | 1.000 |
| 14:24194767:C:A | G85W | 1.000 |
| 14:24189451:G:C | F595L | 0.999 |
| 14:24189451:G:T | F595L | 0.999 |
| 14:24189452:A:G | F595S | 0.999 |
| 14:24189453:A:G | F595L | 0.999 |
| 14:24189483:C:G | G585R | 0.999 |
| 14:24189529:G:C | F569L | 0.999 |
| 14:24189529:G:T | F569L | 0.999 |
| 14:24189531:A:G | F569L | 0.999 |
| 14:24189609:C:G | G543R | 0.999 |
| 14:24189617:C:T | G540D | 0.999 |
| 14:24189618:C:G | G540R | 0.999 |
| 14:24189639:A:G | W533R | 0.999 |
| 14:24189639:A:T | W533R | 0.999 |
| 14:24189645:A:G | W531R | 0.999 |
| 14:24189645:A:T | W531R | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000071113 (14:24188974 A>C), RS1000173037 (14:24191135 G>A), RS1001921706 (14:24190900 C>T), RS1002039918 (14:24192105 A>C), RS1002389168 (14:24195623 G>A,T), RS1002429260 (14:24196808 T>C), RS1002585790 (14:24193525 C>T), RS1002616662 (14:24196546 T>G), RS1002928805 (14:24196308 G>A), RS1003225198 (14:24189891 C>A,T), RS1003409217 (14:24191888 G>C), RS1004725545 (14:24190219 G>A), RS1004817567 (14:24195625 C>T), RS1004945285 (14:24195338 G>A,C), RS1005321411 (14:24191991 T>A)
Disease associations
OMIM: gene MIM:618965 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | affects expression, affects cotreatment, increases methylation | 2 |
| Nickel | increases expression | 2 |
| Valproic Acid | affects expression, increases methylation | 2 |
| sodium arsenite | decreases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| avobenzone | increases expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Atrazine | increases expression | 1 |
| Vehicle Emissions | decreases expression, increases abundance | 1 |
| Caffeine | decreases expression | 1 |
| Carbamazepine | affects expression | 1 |
| Diazinon | increases methylation | 1 |
| Ivermectin | decreases expression | 1 |
| Phenobarbital | affects expression | 1 |
| Selenium | affects cotreatment, increases expression | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Thioacetamide | decreases expression | 1 |
| Tunicamycin | increases expression | 1 |
| Vitamin E | affects cotreatment, increases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Copper Sulfate | decreases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
Cellosaurus cell lines
3 cell lines: 3 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_E0R4 | Ubigene HeLa TM9SF1 KO | Cancer cell line | Female |
| CVCL_TS56 | HAP1 TM9SF1 (-) 1 | Cancer cell line | Male |
| CVCL_TS57 | HAP1 TM9SF1 (-) 2 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.